Suppr超能文献

术前联合放疗及丝裂霉素/5-氟尿嘧啶治疗局部晚期直肠腺癌。

Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma.

作者信息

Burke S J, Percarpio B A, Knight D C, Kwasnik E M

机构信息

Department of Surgery, Waterbury Hospital Health Center, CT 06721, USA.

出版信息

J Am Coll Surg. 1998 Aug;187(2):164-70. doi: 10.1016/s1072-7515(98)00135-5.

Abstract

BACKGROUND

In the treatment of locally advanced rectal carcinoma, radiation therapy before surgery has been shown to decrease local recurrence rates, but has minimal effect on survival. Recently, chemotherapy in combination with preoperative radiation therapy has been shown to be effective for certain malignancies. We postulated that such combination therapy might improve the resectability of advanced rectal cancer.

STUDY DESIGN

During a 4-year period we treated 20 patients with locally advanced adenocarcinoma of the rectum using a protocol of preoperative simultaneous pelvic irradiation (4,030-6,040 cGy) and infusion chemotherapy (5-fluorouracil 100 mg/m2 per day over 96 hours and mitomycin 10 mg/m2) followed by surgical resection. Effects of therapy on resectability, tumor size, recurrence and survival, and complications of treatment were evaluated.

RESULTS

Minimal toxicity was observed and all patients completed their scheduled preoperative therapy. Reduction in tumor size after chemoradiation, as measured by CT scan, averaged 61% (range 20-100%). Twenty percent had a complete pathologic response to preoperative therapy, with no tumor found in the surgical specimen. Using Kaplan-Meier survival curves, the 5-year survival was estimated to be 64+/-11%, and cancer free and local pelvic control rates were 41+/-12% and 88+/-8% respectively.

CONCLUSIONS

We believe that preoperative combination radiation and chemotherapy may provide significant benefit for patients with locally advanced rectal cancer, and that further, large scale studies of this treatment regimen are warranted.

摘要

背景

在局部晚期直肠癌的治疗中,术前放疗已被证明可降低局部复发率,但对生存率影响极小。最近,化疗联合术前放疗已被证明对某些恶性肿瘤有效。我们推测这种联合治疗可能会提高晚期直肠癌的可切除性。

研究设计

在4年期间,我们采用术前同步盆腔照射(4030 - 6040 cGy)和静脉化疗(5 - 氟尿嘧啶100 mg/m² 每天持续96小时,丝裂霉素10 mg/m²)然后手术切除的方案治疗了20例局部晚期直肠腺癌患者。评估了治疗对可切除性、肿瘤大小、复发和生存以及治疗并发症的影响。

结果

观察到毒性极小,所有患者均完成了预定的术前治疗。通过CT扫描测量,放化疗后肿瘤大小平均缩小61%(范围20% - 100%)。20%的患者对术前治疗有完全病理反应,手术标本中未发现肿瘤。使用Kaplan - Meier生存曲线,估计5年生存率为64±11%,无癌生存率和局部盆腔控制率分别为41±12%和88±8%。

结论

我们认为术前放化疗联合可能为局部晚期直肠癌患者带来显著益处,并且有必要对这种治疗方案进行进一步的大规模研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验